Stock screenerAll disclosures →
EDGAR →
NAMS
Conviction 2HealthcareScan · Thu, Sep 24, 2026NewAmsterdam Pharma Co N.V. (NAMS) closed at $22.75 (+0.31%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 40, RS Rating 18, -45.1% from its 52-week high, -35.4% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
NAMS$22.75+0.31%
ResistanceSupportVol 14Insider buyInsider sell2
Vol MA14 2.16M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price22.75
Change+0.31%
Gap-0.33%
Rel volume1.11×
Avg volume1.78M
Avg $ vol41.55M
SMA 2023.67
SMA 5026.55
SMA 20031.52
Price vs 50-14.31%
Price vs 200-27.83%
MA stackbearish
50/200 cross—
Supertrenddown · 25.68
RSI (14)40
MACD hist0.16
MACD crossbull · 2d
Stoch %K / %D33 / 37
ADX (14)44
+DI / −DI12 / 22
RSI divergence—
MACD divergence—
ATR %6.09%
ADR %5.75%
52w high41.45
52w low21.16
From 52w high-45.11%
Above 52w low+7.51%
New 52w highNo
SqueezeOff
Bollinger width29.50%
%B0.37
Donchian pos26.29%
Donchian high27.60
Donchian low21.02
AVWAP (52w high)29.46
vs AVWAP high-22.77%
AVWAP (52w low)22.46
vs AVWAP low+1.31%
OBV trendUp
Chaikin MF (20)-0.02
Today vs 20d1.11×
Avg vol (14d)2.16M
Avg vol (20d)1.78M
Avg $ vol (20d)41.55M
Market cap2.72B
RS Rating18 / 99
RS 3m (vs SPY)-32.79%
RS 6m (vs SPY)-43.45%
RS line new highNo
Trend template0/8
Technical rank16.7
1 week+3.74%
1 month-16.79%
3 months-28.30%
6 months-26.64%
1 year-14.70%
YTD-35.37%
P/E-13.34
P/B4.31
P/S120.85
P/FCF-18.37
EPS-1.72
Div yield—
ROE-32.28%
ROA-28.93%
Debt/Eq—
Current9.03
EV/EBITDA-10.18
Gross margin—
Net margin-905.74%
Rev growth-50.61%
EPS growth15.64%
Price target53.75
Target upside136.26%
Analyst ratingBuy
Institutional104.26%
Ent. value2.3B
Revenue3.7M
Net income-64.14M
Gross profit—
Free cash flow-148.03M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out116.9M
Employees100
ListedWed, Nov 23, 2022
Free float62.23M
Float %53.2%
Short interest13.39M
Days to cover13.4d
Short volume43.2%
Squeeze score69 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.52 vs −$0.48
Last surprise-8.3% miss
Setup gradeD
Conviction2 / 100
Pattern quality—
Tech rank16.7 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance28.87
Support22.91
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- NewAmsterdam Pharma Co N.V.: Ownership stake amendedSEC EDGAR · Tue, Sep 22, 2026
- NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)Yahoo Finance · Mon, Sep 21, 2026
- NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% RunYahoo Finance · Sun, Sep 20, 2026
Congress activity
Disclosed STOCK Act trades in NAMS
No recent disclosed trades by Congress in NAMS. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in NAMS · open-market 1 buy · 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Davidson Michael H. Chief Executive Officer · Ordinary Shares · 2026-09-14 | Buy | 10K | $227K | 2026-09-14 | 2026-09-15 |
Smither John W Director · Ordinary Shares · 2026-09-04 | Sell | 1.6K | $41K | 2026-09-04 | 2026-09-09 |
Kastelein Johannes Jacob Pieter Chief Scientific Officer · Ordinary Shares · 2026-08-24 | Exercise | 125K | — | 2026-08-24 | 2026-08-25 |
Kastelein Johannes Jacob Pieter Chief Scientific Officer · Ordinary Shares · 2026-08-24 | Sell | 125K | $3.4M | 2026-08-24 | 2026-08-25 |
Kastelein Johannes Jacob Pieter Chief Scientific Officer · Option (right to buy) · 2026-08-24 | Exercise | 125K | — | 2026-08-24 | 2026-08-25 |
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-07-20 | Sell | 70.2K | $2.1M | 2026-07-20 | 2026-07-22 |
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-07-20 | Sell | 31.89K | $990K | 2026-07-20 | 2026-07-22 |
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-07-20 | Exercise | 25K | $298K | 2026-07-20 | 2026-07-22 |
Kooij Louise Frederika Chief Accounting Officer · Ordinary Shares · 2026-07-20 | Exercise | 80K | $894K | 2026-07-20 | 2026-07-22 |
Kooij Louise Frederika Chief Accounting Officer · Option (right to buy) · 2026-05-26 | Exercise | 5K | $0 | 2026-05-26 | 2026-05-27 |
SEC filings
EDGAR filings in NAMS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.